Advertisement
Advertisement
April 23, 2021
ISTH Releases Interim Guidance on Vaccine-Induced Immune Thrombotic Thrombocytopenia
April 23, 2021—The International Society on Thrombosis and Hemostasis (ISTH) has issued interim guidance for the diagnosis and treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). ISTH advised that this guidance, which builds upon the work of the society’s international partners, should be used to inform the management of suspected thrombosis in patients who have recently received the AstraZeneca or Johnson & Johnson vaccines.
According to ISTH, the report is a complement to ISTH’s April 9 statement on blood clots associated with COVID-19 vaccination. As a reminder, the ISTH reiterated that COVID-19 is associated with a risk of hospitalization and death and noted that the reported combination of blood clots and low blood platelets is exceedingly rare, and the overall benefits of the AstraZeneca vaccine and the Johnson & Johnson vaccine outweigh the risks of these rare thromboembolic side effects advised ISTH. The ISTH COVID-19 Response Task Force, represented by an international committee of medical leaders, informed and reviewed this guidance, finalized on April 20, 2021.
The ISHT Guidance on VITT and the VITT Diagnostic Flow Chart are available on the society’s website. Additional ISTH statements and announcements are available on the society's website here.
Advertisement
Advertisement
